TrialLeukemia2019

Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

G Fraser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.